GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyxone AB (FRA:4CX) » Definitions » Notes Receivable

Cyxone AB (FRA:4CX) Notes Receivable : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cyxone AB Notes Receivable?

Cyxone AB's Notes Receivable for the quarter that ended in Jun. 2024 was €0.00 Mil.


Cyxone AB Notes Receivable Historical Data

The historical data trend for Cyxone AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyxone AB Notes Receivable Chart

Cyxone AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Cyxone AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cyxone AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Cyxone AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Cyxone AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyxone AB Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, 215 32
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod.

Cyxone AB Headlines

No Headlines